Re-Trade in a Veterinary Practice Sale: How to Prevent It in 2026

July 27, 2026

Veterinarian reviewing veterinary practice sale documents

Re-Trade in a Veterinary Practice Sale: How to Prevent It in 2026

Key takeaways

A re-trade is when a buyer cuts the agreed price after signing the LOI, useing the 60-to-90-day exclusivity window when you’re legally locked in and can’t talk to other buyers.
Two conditions make re-trades possible: a single buyer and disorganized financials. Remove either one and the risk drops sharply.
A competitive process is the single strongest protection. When you entered exclusivity having run real competition, you have other buyers who said yes — and that walk-away option changes what the buyer in front of you will risk.
Clean, documented, defensible normalized EBITDA removes the buyer’s basis for a price reduction. When the Quality of Earnings review confirms what you presented, there is no opening for a price reduction based on financial discrepancies.
Not every re-trade is opportunistic. Some are legitimate — they surface a real problem. The ones that are legitimate are also the ones clean preparation would have caught before the buyer did.

I sat with a vet a couple of years ago who had just lived through the thing I spend a lot of energy trying to help owners avoid. She’d spent nine months going through a sale process, gotten a solid offer in writing, signed the Letter of Intent, and then watched the buyer come back six weeks later — right before the exclusivity window closed — with a number that was $600,000 lower than what she’d agreed to.

The stated reason was “operational risk identified during diligence.” The actual trigger was simpler: she’d gone in with one buyer, no competition, and disorganized books that left room for interpretation. By the time the re-trade landed, she had no leverage.

She was nine months in, emotionally done, already mentally moved on. She took the lower number.

She didn’t have to. That outcome was preventable.

And the way you prevent it starts well before anyone signs anything.

What a re-trade in a veterinary practice sale actually is

A re-trade is when a buyer reduces the agreed purchase price — or attempts to change other material deal terms — after the Letter of Intent is signed but before the purchase agreement closes.

The Letter of Intent (LOI) is the non-binding document that outlines the agreed headline price and key deal terms. It’s not the final contract — that’s the purchase agreement — but it marks the moment when both sides have agreed, in principle, on what the deal looks like.

It also typically triggers the exclusivity period.

The exclusivity period is a contractual window, typically 60 to 90 days, during which the seller is legally prohibited from talking to other potential buyers. Per law firm Mintz’s seller guidance on LOI negotiations, exclusivity is the buyer’s single most valuable LOI provision — and the sellers’ leverage disappears the moment they agree to it.

That shift in leverage is the mechanism a re-trade uses. Before the LOI, competition among buyers keeps you in control.

After the LOI, you’re locked in with one buyer, and walking away means restarting the entire process, losing months, and potentially losing momentum with any buyers who’ve moved on since your initial conversations. The buyer in front of you knows this.

The short answer: A re-trade in a veterinary practice sale is when a buyer uses the exclusivity period — the window when you can’t say yes to anyone else — to argue that your practice is worth less than what they offered. Sometimes the argument is legitimate. Sometimes it isn’t. Either way, the conditions that allow it are within your control.

Why the leverage shifts so hard after the LOI — and what buyers do with it

The re-trade isn’t unique to veterinary practice sales. It’s a pattern in M&A broadly.

Divestopedia’s definition of re-trading notes it bluntly: the buyer “is often taking advantage of the seller because the seller may not have other prospective buyers waiting.” That’s the whole mechanism.

What makes it predictable in vet practice transactions specifically is the typical timeline. A serious sale process — from first conversations through closing — runs anywhere from 6 to 12 months for most practices.

By the time a seller reaches the LOI stage, they’ve invested months of time, disclosed sensitive financial and operational data, and emotionally prepared to move on. Walking away has a real psychological cost that compounds the financial one.

The Goodwin law firm published data showing that M&A exclusivity periods have lengthened materially since 2021. In 2021, only about 6 percent of PE-related deals involved exclusivity periods longer than 60 days.

By 2022, nearly 40 percent did. That means sellers are locked in longer, which means the buyer has more time to conduct a thorough Quality of Earnings review and more runway to surface — or manufacture — a justification for a lower price.

Some buyers place stretched bids to win exclusivity, intending to renegotiate once they’re the only buyer in the room. According to the M&A advisory firm Corum Group’s guidance for sellers, “most buyers are honest” but some have “a reputation for doing retrades as a deliberate strategy.” Buyer reputation is something a well-run process surfaces before the LOI, not after.

Veterinarian reviewing financial documents at a practice desk, looking down at papers, candid and unposed

What triggers a re-trade: legitimate versus opportunistic

Not every re-trade is a power move. Some are legitimate, and it’s worth being honest about the distinction.

Legitimate re-trades come from genuinely new information the buyer’s due diligence uncovered that wasn’t visible in the materials you shared during the sale process. Common triggers include:

An add-back that doesn’t hold up. You claimed a personal vehicle expense as an add-back, but the documentation doesn’t support the full amount, or a portion of it was genuinely practice-related. The buyer’s Quality of Earnings review — the deep financial review the buyer’s accountants run to test whether your normalized EBITDA holds up under scrutiny — finds the gap and prices it in.
Revenue concentrated in a departing doctor. If 40 percent of your collections trace to an associate who has already given notice, and the buyer discovers this during diligence, the adjustment is defensible.
A lease with unfavorable assignment terms. A landlord who won’t assign the lease without a significant rent increase at change of ownership is a real transaction risk — and a fair reason for a price discussion.
Compliance exposure the seller didn’t know about. Coding errors, contractor misclassification, or regulatory violations that surface in a legal review can carry real liability, and a buyer pricing in that risk is acting rationally.

Opportunistic re-trades look different. They come with round numbers and loose explanations. “We found some operational risk” without specifics.

A $400,000 reduction with no line-item justification. “The market has softened since we put the offer in” — when the market data doesn’t support that framing. Per the Corum Group’s analysis of re-trade patterns, push back when the justification is vague rather than quantifiable.

The tell is specificity. A legitimate re-trade comes with a number, a line item, and a document.

An leverage-driven one comes with a narrative designed to soften your resistance rather than a calculation designed to reflect a real change in value.

The two things that prevent a re-trade in a veterinary practice sale

Everything I’ve seen across the deals we’ve worked on over the past four-plus years points to two root causes when a seller gets re-traded. Remove one, and the risk drops substantially.

Remove both, and it’s close to zero.

Root cause 1: a single buyer with no competition.

When you go into exclusivity with one buyer and no other serious options in play, that buyer is the only path forward. Your walk-away threat isn’t credible because walking away costs you everything. A competitive process is the structural solution.

When multiple qualified buyers bid on the same timeline — each aware that others are in the room — you sign the LOI based on both price and the buyer’s reputation and track record. You can avoid buyers known for material post-LOI price reductions before you ever give them exclusivity.

And once you’re in exclusivity, you have other buyers who expressed serious interest and have not been told no. That’s a real walk-away option, and a buyer who knows it is far less likely to test it.

This is what the Elite Selling System is built to create: a vetted pool of buyers competing in a structured window, the way a doorman with a velvet rope lets in only the right people. The competition produces a higher headline price.

The credible fallback makes that headline price durable through diligence.

Root cause 2: disorganized or undocumented financials.

A buyer’s Quality of Earnings review isn’t designed to protect your valuation. It’s designed to protect theirs.

If your add-backs are undocumented, your monthly financials are inconsistent, or your normalized EBITDA hasn’t been assembled from a defensible methodology, the QoE process will surface those gaps — and each gap can become a specific basis for a pricing discussion.

Clean preparation reduces that exposure. The data-room guidance from M&A advisory sources is consistent: a data room that’s 70 to 80 percent complete before going to market, with three years of organized tax returns, a documented add-back schedule with supporting backup for every line, and consistent monthly close processes, closes deals faster and with fewer re-trades. When the buyer’s review confirms what you presented, there is much less room for a pricing reset.

What the due diligence process actually looks like — and where re-trades emerge

Knowing where in the timeline re-trades typically occur helps you prepare for the right moment.

A standard veterinary practice due diligence process covers three areas: financial, operational, and legal. Buyers reviewing financial records look at tax returns (typically 3 years minimum), bank statements, profit and loss statements, collections records, staff compensation, and overhead costs.

Operational review covers employee turnover patterns, appointment book trends, equipment condition, and fee benchmarks versus local markets. Legal review covers leases, licensing compliance, employment contracts, and vendor agreements.

Normalized EBITDA — the practice’s operating profit after stripping out personal expenses and one-time items, adjusted to what a hired medical director would cost rather than an owner’s actual draw — is the central number buyers test. The multiple — the multiplier buyers apply to that profit to set the price — is what you negotiated in the LOI. A re-trade is almost always a challenge to the EBITDA, not to the multiple.

The most common EBITDA challenges:

What gets challenged	Why it matters
Owner compensation add-back	If the owner’s stated market salary is below what a comparable medical director would cost, buyer adjusts downward
Personal expenses run through the practice	Without invoices and clear documentation, the buyer discounts the add-back
One-time revenue items included in trailing 12 months	Settlement payments, emergency revenue spikes — buyers normalize these out
Revenue concentration (single doctor or single referral source)	High concentration = risk premium = lower multiple or adjusted price
Equipment with deferred maintenance	Capital expenditure requirement offsets the EBITDA the buyer is paying for

Each of these is visible in advance. Each can be documented, explained, and defended before the buyer’s accountants ever open the data room. The practice of managing your own financials as though a QoE could be launched tomorrow is the single most durable protection against re-trades.

What your options are if a re-trade lands anyway

Even with a competitive process and clean financials, you might face a re-trade attempt if the buyer uncovers something genuinely material. Here’s how I’ve watched owners work through it.

Push back first, with specifics. Ask the buyer to quantify the finding. What exact line item changed?

What is the dollar impact of that specific item? A buyer with a legitimate concern will have a number and a document.

A buyer fishing for leverage will have a narrative. When you ask for specifics, you separate the two.

Check whether the issue was disclosed. If the concern the buyer is raising was visible in the materials you shared — it was in the financial package, it was in the data room, it was disclosed during the quality-of-information period before the LOI — then the buyer’s argument weakens substantially. They agreed to the price knowing what was there.

Know your walk-away number before you go in. The time to decide how much price reduction you’re willing to accept, if any, is not when you’re sitting across from a buyer’s deal team at month three of diligence. It’s before you sign the LOI.

Establish that number in advance, document it for yourself, and don’t let the momentum of a nine-month process push you below it.

Understand your alternatives. A seller who ran a competitive process has options. A seller who went in with a single buyer has fewer.

The credible walk-away threat — “we have another party who made a serious offer and we can restart” — is what gives you real negotiating leverage when a re-trade is attempted.

Per Corum Group’s guidance on retrades, sellers have three options: accept if the reduction is modest and the deal is otherwise strong; negotiate if the concern is legitimate; terminate if the justification is weak and alternatives exist. The right answer depends almost entirely on what your process looks like before the re-trade attempt lands.

Veterinarian consulting with a financial advisor at a practice conference table, both looking at documents, relaxed and professional

What holdbacks have to do with any of this — and what they don’t

A holdback — a portion of the purchase price, typically 5 to 15 percent, that the buyer retains after closing for a defined period to cover potential warranty claims — is sometimes confused with a re-trade. They’re not the same thing.

A holdback is a normal, negotiated deal term. It’s agreed to before closing as part of the purchase agreement.

In a veterinary practice sale, funds are wired directly to you at closing; the holdback is the amount the buyer keeps back temporarily to secure your representations about the practice’s condition. The CBIZ analysis of M&A trends notes that representations and warranties (R&W) insurance — a policy that covers breaches of reps — can reduce or eliminate holdbacks in larger transactions, because the buyer can pursue the insurance rather than keeping your money.

A re-trade is something different: a unilateral attempt to change the headline price after the LOI is signed but before closing. A holdback is a structural term; a re-trade is a negotiating tactic.

Understanding the difference matters because buyers occasionally use holdback expansion as a re-trade vehicle — “we need to increase the holdback from 10 percent to 20 percent based on diligence findings” — which is economically similar to a price reduction even if it’s presented differently.

For more on how practice sale economics work overall, see our full guide to selling a veterinary practice and the veterinary practice valuation guide.

How to run a process that makes re-trades structurally difficult

The practical checklist is shorter than most owners expect.

Before you go to market:

Get your financial house in order. Three years of organized tax returns and P&Ls, a clean add-back schedule with supporting documentation for every adjustment, and a normalized EBITDA number assembled from a defensible methodology.

This is the work we do on every practice before we ever put it in front of a buyer — a thorough pre-sale financial review built around exactly the kind of scrutiny the buyers’ accountants will run, but before any of those buyers see your numbers. That gives us time to fix anything that wouldn’t survive a deep review.

Understand what your walk-away number is. Not abstractly — specifically.

What is the minimum net price at which you’d proceed? What is the minimum cash-at-close?

Build that into your LOI negotiations.

During buyer selection:

Run a competitive process. Contact enough qualified buyers — the guidance from practice sale attorneys is consistently 6 to 8 — to get simultaneous bids on the same timeline.

Review buyer reputation as rigorously as you review price. A buyer who has a history of re-trading in prior deals is identified by advisors who track deal history.

Price is not the only variable in LOI selection.

In the LOI:

Keep the exclusivity window short. Per Mintz’s seller guidance, sellers should target 30 to 45 days; resist open-ended automatic extensions.

The longer the exclusivity window, the more time the buyer has to pressure you during diligence and the weaker your walk-away threat becomes. Negotiate the LOI so that any price adjustment requires a specific, documented finding — not a general claim about risk.

During diligence:

Respond to information requests promptly and completely. Disorganized or slow data room responses signal vulnerability and give buyers the narrative that records aren’t clean.

A data room that’s ready before diligence starts projects confidence and removes one of the most common re-trade pretexts. Per data room preparation guidance, a well-organized data room can accelerate diligence timelines by 2 to 4 weeks and materially reduce re-trade risk.

See our guide on who to sell your veterinary practice to for more on buyer selection, and our practice valuation guide for how EBITDA documentation affects the number buyers pay.

What the 2026 market means for re-trade risk

The Capstone Partners April 2026 Pet Sector M&A Update reported 18 announced or completed pet-sector transactions in year-to-date 2026 — more than double the 8 recorded in the same period of 2025. The Vet & Health segment led with 9 of those deals.

Strategic buyer activity climbed to 10 transactions in YTD 2026 compared to just 3 in the prior year period, with PE platform and add-on activity also recovering.

More deal volume means more buyers in the market, which means more competition is genuinely available to sellers who structure their process correctly. It also means buyers are moving faster, which can compress diligence timelines and reduce the window for extended re-trade negotiations.

The period from 2023 through mid-2025, when PE-backed groups pulled back in some cases due to higher financing costs, created conditions where re-trade attempts were more common — fewer buyers bidding meant less competition and more buyer leverage at every stage, including post-LOI. The 2026 recovery in deal activity changes that dynamic.

More buyers competing for quality practices restores seller leverage during the pre-LOI period. But it doesn’t eliminate the leverage shift that happens once you sign into exclusivity with a single buyer. The structural protection — a competitive process — still matters in a hot market.

The veterinary practice consolidators page covers the buyer landscape in more depth, including which buyer types are most active and what they’re paying attention to in current diligence.

The bottom line

The vet I mentioned at the start took $600,000 less than she’d agreed to. Not because her practice was worth less.

Because she went in with one buyer, disorganized books, and no plan for what she’d do if the buyer came back with a lower number.

The outcome wasn’t inevitable. Every factor that made the re-trade possible was fixable before the process started.

The books could have been cleaned. The process could have run with multiple buyers.

The walk-away number could have been established in advance.

What she sold is still a good practice. The buyer she closed with is a reasonable buyer.

But the number was lower than it had to be, and the gap wasn’t small.

That’s the version of this story I’d rather not tell. The version I’d rather tell is the owner who came in with clean financials, ran a full competitive process, signed the LOI with a buyer who’d competed for the right to be in the room, and sat through diligence with the quiet confidence of someone who knows the numbers will hold.

That version happens when the process is built right from the beginning.

When you are ready, request a free, confidential practice value estimate.

When we prepare a practice for sale, the financial review comes first — before the first buyer conversation. We build a normalized EBITDA package the buyer’s accountants can verify, assemble the add-back documentation, and identify anything that wouldn’t survive a serious QoE before we ever hand it to a buyer.

That preparation is the foundation of a process where re-trades don’t land.

We work on a success-based model: no upfront fees, no retainer, compensated only when a deal closes and only out of the value we create above what the owner would have received on their own.

Frequently asked questions

What is a re-trade in a veterinary practice sale in 2026?

A re-trade is when a buyer lowers the agreed purchase price — or changes other material deal terms — after signing the Letter of Intent but before the purchase agreement closes. It most often happens during the exclusivity period, when the seller is contractually prohibited from talking to other buyers.

The buyer uses that leverage to argue that due diligence uncovered risks that justify a lower number. In some cases those concerns are legitimate.

In others, the buyer simply placed a stretched bid before diligence and expected to revisit the price during diligence if the financial support did not hold up.

How common are re-trades in veterinary practice sales?

Re-trades are not universal, but they are predictable when the conditions that enable them exist: a seller with a single buyer, disorganized financials, and no credible fallback. Exclusivity periods of 60 to 90 days are standard in veterinary M&A, and during that window the seller’s leverage disappears unless they have a competitive process already in place.

Sellers who go to market with one buyer and unvetted add-backs face the highest re-trade risk. Sellers who run a structured competitive process and present clean, documented financials face the lowest.

Why do buyers attempt re-trades after signing the LOI?

Buyers attempt re-trades because the leverage math shifts sharply once a seller signs an LOI and enters exclusivity. Before the LOI, competition among buyers keeps the seller in control.

After the LOI, the seller is locked in with one buyer for 60 to 90 days — walking away means restarting the entire process, losing months of time, and potentially losing momentum with other buyers. Some buyers take a more assertive posture after exclusivity by making stretched bids before diligence, then using due diligence to find justification for a lower price.

Others raise genuine concerns uncovered during their Quality of Earnings review.

What triggers a legitimate re-trade versus an leverage-driven one?

A legitimate re-trade is triggered by genuinely new information: a major expense that wasn’t disclosed, an add-back that doesn’t hold up to scrutiny, a lease with unfavorable assignment terms, or revenue that turns out to be concentrated in one doctor who is leaving. A leverage-driven re-trade is triggered by the seller’s reduced leverage rather than genuinely new information.

The buyer raises vague concerns about operational risk or market conditions that were visible long before the LOI was signed. The tell is specificity: legitimate re-trades come with a quantified adjustment tied to a specific finding; leverage-driven ones come with a round number and a loose explanation.

How does a competitive process prevent a re-trade in a veterinary practice sale?

A competitive process prevents re-trades in two ways. First, when multiple buyers bid on the same timeline, the seller selects the LOI based on both price and buyer quality — they can avoid buyers with a pattern of post-LOI price reductions.

Second, once in exclusivity, a seller who ran a competitive process has other buyers who expressed strong interest and have not been told no. That credible walk-away option changes the power dynamic during diligence.

A buyer who knows the seller can realistically restart with another serious buyer is far more cautious about attempting an post-LOI price reduction.

What should a seller do if a buyer attempts a re-trade?

A seller facing a re-trade has three options: accept the adjusted terms if the reduction is modest and the deal is otherwise strong; negotiate by pushing back and asking the buyer to quantify the specific finding that justifies the reduction; or terminate if the reduction is material and the justification is weak. The right response depends on how strong the seller’s alternatives are.

A seller who ran a competitive process and has other interested buyers has real leverage to push back or walk. A seller with no alternatives is in a weaker position, which is exactly why the process structure matters before the LOI is ever signed.

What financial preparation reduces re-trade risk in a veterinary practice sale?

The most effective financial preparation is a clean, documented, and defensible normalized EBITDA package assembled before going to market. This means organizing three years of tax returns and profit-and-loss statements, building an add-back schedule with clear supporting documentation for every adjustment, ensuring that owner compensation adjustments are benchmarked to market rates for a hired medical director, and having consistent monthly close processes so the numbers tell a coherent story.

When a buyer’s Quality of Earnings review confirms what the seller presented, there is no opening for a re-trade based on financial discrepancies.

What is a holdback and how does it relate to a re-trade?

A holdback is a portion of the purchase price — typically 5 to 15 percent — that the buyer retains after closing for a defined period, usually 12 to 24 months, to secure the seller’s representations and warranties. It is different from a re-trade: a holdback is a normal, negotiated deal term agreed to before closing; a re-trade is a unilateral attempt to reduce the headline price after the LOI is signed.

In veterinary practice sales, funds are wired directly to the seller at closing; the holdback is the amount the buyer keeps back temporarily to cover potential warranty claims. Representations and warranties insurance can reduce or eliminate holdbacks in larger transactions.